GI Pharmacology Flashcards

1
Q

What is 5-aminosalicyclic acid (5-ASA)

A

acts locally as an anti-inflammatory.

released in the colon and is not absorbed.

may inhibit prostaglandin synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Sulphasalazine

a combination of ? and 5-ASA

A

sulphapyridine (a sulphonamide)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Sulphasalazine has few side effects due to the sulphapyridine moiety

A

FALSE

many side-effects are due to the sulphapyridine moiety

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Sulphasalazine may cause which types of anaemia?

A

Heinz body anaemia, megaloblastic anaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Sulphasalazine sepcific side effects?

A

: rashes, oligospermia, headache

lung fibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

delayed release form of 5-ASA

A

Mesalazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Aminosalicylates are associated with a variety of haematological adverse effects, including

A

agranulocytosis - FBC is a key investigation in an unwell patient taking them.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Mesalazine - sulphapyridine side-effects seen in patients taking sulphasalazine are avoided
mesalazine is still however associated with side-effects such as

A

GI upset, headache, agranulocytosis, pancreatitis*, interstitial nephritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Olsalazine

two molecules of 5-ASA linked by a diazo bond, which is broken by colonic bacteria

A

true

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

pancreatitis is 7 times more common in patients taking ? than sulfasalazine

A

mesalazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Antidiarrhoeal agents - Opioid agonists include

A

loperamide

diphenoxylate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Cholestyramine is

A

bile acid sequestrant used in the management of hyperlipidaemia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Cholestyramine works by?

A

decreases bile acid reabsorption in the small intestine, therefore upregulating the amount of cholesterol that is converted to bile acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Cholestyramine effect on lipid profile

A

reduce LDL cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cholestyramine Adverse effects

A

abdominal cramps and constipation
decreases absorption of fat-soluble vitamins
cholesterol gallstones
may raise level of triglycerides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Metoclopramide is

A

D2 receptor antagonist* mainly used in the management of nausea.

17
Q

Metoclopramide causes hyper/hypoprolactinaemia?

A

hyperprolactinaemia

18
Q

Metoclopramide neuro s/e

A

extrapyramidal effects
tardive dyskinesia
parkinsonism

19
Q

Metoclopramide should be avoided in

A

bowel obstruction, but may be helpful in paralytic ileus.

20
Q

Metoclopramide it is also a mixed 5-HT3 receptor antagonist/5-HT4 receptor agonist

A

true

21
Q

Proton pump inhibitors (PPI) work by?

A

rreversible blockade of H+/K+ ATPase of the gastric parietal cell.

22
Q

Proton pump inhibitors (PPI) electrolyte disturbances?

A

hyponatraemia, hypomagnasaemia

23
Q

Proton pump inhibitors (PPI) adverse effects?

A

osteoporosis → increased risk of fractures
microscopic colitis
increased risk of Clostridium difficile infections

24
Q

Refeeding syndrome describes

A

metabolic abnormalities which occur on feeding a person following a period of starvation. It occurs when an extended period of catabolism ends abruptly with switching to carbohydrate metabolism

25
Q

Refeeding syndrome metabolic consequences

A

hypophosphataemia
hypokalaemia
hypomagnesaemia
abnormal fluid balance

26
Q

hypomagnesaemia may predispose to?

A

may predispose to torsades de pointes

27
Q

Refeeding syndrome may avoided by identifying patients at a high-risk of developing refeeding syndrome:

Patients are considered high-risk if one or more of the following:

A

BMI < 16 kg/m2
unintentional weight loss >15% over 3-6 months
little nutritional intake > 10 days
hypokalaemia, hypophosphataemia or hypomagnesaemia prior to feeding (unless high)

28
Q

Refeeding syndrome may avoided by identifying patients at a high-risk of developing refeeding syndrome:

Patients are considered high-risk if TWO or more of the following:

A

BMI < 18.5 kg/m2
unintentional weight loss > 10% over 3-6 months
little nutritional intake > 5 days
history of: alcohol abuse, drug therapy including insulin, chemotherapy, diuretics and antacids

29
Q

NICE recommend that if a patient hasn’t eaten for > 5 days, aim to re-feed at no more than ?% of requirements for the first 2 days.

A

NICE recommend that if a patient hasn’t eaten for > 5 days, aim to re-feed at no more than 50% of requirements for the first 2 days.